Openly accessible

Is adaptive therapy natural?

Thomas, Frederic, Donnadieu, Emmanuel, Charriere, Guillaume M., Jacqueline, Camille, Tasiemski, Aurelie, Pujol, Pascal, Renaud, Francois, Roche, Benjamin, Hamede, Rodrigo, Brown, Joel, Gatenby, Robert and Ujvari, Beata 2018, Is adaptive therapy natural?, PLoS biology, vol. 16, no. 10, doi: 10.1371/journal.pbio.2007066.

Attached Files
Name Description MIMEType Size Downloads
ujvari-isadaptivetherapy-2018.pdf Published version application/pdf 2.32MB 27

Title Is adaptive therapy natural?
Author(s) Thomas, Frederic
Donnadieu, Emmanuel
Charriere, Guillaume M.
Jacqueline, Camille
Tasiemski, Aurelie
Pujol, Pascal
Renaud, Francois
Roche, Benjamin
Hamede, Rodrigo
Brown, Joel
Gatenby, Robert
Ujvari, BeataORCID iD for Ujvari, Beata orcid.org/0000-0003-2391-2988
Journal name PLoS biology
Volume number 16
Issue number 10
Article ID e2007066
Total pages 12
Publisher Public Library of Science
Place of publication San Francisco, Calif.
Publication date 2018-10
ISSN 1544-9173
1545-7885
Summary Research suggests that progression-free survival can be prolonged by integrating evolutionary principles into clinical cancer treatment protocols. The goal is to prevent or slow the proliferation of resistant malignant cell populations. The logic behind this therapy relies on ecological and evolutionary processes. These same processes would be available to natural selection in decreasing the probability of an organism's death due to cancer. We propose that organisms' anticancer adaptions include not only ones for preventing cancer but also ones for directing and retarding the evolution of life-threatening cancer cells. We term this last strategy natural adaptive therapy (NAT). The body's NAT might include a lower than otherwise possible immune response. A restrained immune response might forego maximum short-term kill rates. Restraint would forestall immune-resistant cancer cells and produce long-term durable control of the cancer population. Here, we define, develop, and explore the possibility of NAT. The discovery of NAT mechanisms could identify new strategies in tumor prevention and treatments. Furthermore, we discuss the potential risks of immunotherapies that force the immune system to ramp up the short-term kill rates of malignant cancer cells in a manner that undermines the body's NAT and accelerates the evolution of immune resistance.
Language eng
DOI 10.1371/journal.pbio.2007066
Field of Research 06 Biological Sciences
11 Medical And Health Sciences
07 Agricultural And Veterinary Sciences
HERDC Research category C1 Refereed article in a scholarly journal
Copyright notice ©2018, Thomas et al.
Free to Read? Yes
Use Rights Creative Commons Attribution licence
Persistent URL http://hdl.handle.net/10536/DRO/DU:30114742

Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in TR Web of Science
Scopus Citation Count Cited 1 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 91 Abstract Views, 27 File Downloads  -  Detailed Statistics
Created: Fri, 26 Oct 2018, 14:29:22 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.